Display options
Cite
Lewinsohn DA, Swarbrick GM, Park B, et al. Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. NPJ Vaccines. 2017;2doi: 10.1038/s41541-017-0008-6.
Lewinsohn, D. A., Swarbrick, G. M., Park, B., Cansler, M. E., Null, M. D., Toren, K. G., Baseke, J., Zalwango, S., Mayanja-Kizza, H., Malone, L. L., Nyendak, M., Wu, G., Guinn, K., McWeeney, S., Mori, T., Chervenak, K. A., Sherman, D. R., Boom, W. H., & Lewinsohn, D. M. (2017). Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. NPJ vaccines, 2. https://doi.org/10.1038/s41541-017-0008-6
Lewinsohn, Deborah A, et al. "Comprehensive definition of human immunodominant CD8 antigens in tuberculosis." NPJ vaccines vol. 2 (2017). doi: https://doi.org/10.1038/s41541-017-0008-6
Lewinsohn DA, Swarbrick GM, Park B, Cansler ME, Null MD, Toren KG, Baseke J, Zalwango S, Mayanja-Kizza H, Malone LL, Nyendak M, Wu G, Guinn K, McWeeney S, Mori T, Chervenak KA, Sherman DR, Boom WH, Lewinsohn DM. Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. NPJ Vaccines. 2017;2. doi: 10.1038/s41541-017-0008-6. Epub 2017 Apr 03. PMID: 28775896; PMCID: PMC5538316.
Copy Download .nbib Format: NLM
Share it on

NPJ Vaccines. 2017;2. doi: 10.1038/s41541-017-0008-6. Epub 2017 Apr 03.

Comprehensive definition of human immunodominant CD8 antigens in tuberculosis.

NPJ vaccines

Deborah A Lewinsohn, Gwendolyn M Swarbrick, Byung Park, Meghan E Cansler, Megan D Null, Katelynne G Toren, Joy Baseke, Sarah Zalwango, Harriet Mayanja-Kizza, LaShaunda L Malone, Melissa Nyendak, Guanming Wu, Kristi Guinn, Shannon McWeeney, Tomi Mori, Keith A Chervenak, David R Sherman, W Henry Boom, David M Lewinsohn

Affiliations

  1. Division of Infectious Diseases, Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
  2. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  3. Uganda-CWRU Research Collaboration, Kampala, Uganda.
  4. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
  5. Tuberculosis Research Unit, Case Western Reserve University, Cleveland, OH, USA.
  6. Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
  7. Center for Infectious Disease Research, formerly Seattle Biomedical Research Institute, Seattle, WA, USA.
  8. Department of Global Health, University of Washington, Seattle, WA, USA.
  9. Division of Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA.
  10. Portland Veterans Administration Medical Center, Portland, OR, USA.

PMID: 28775896 PMCID: PMC5538316 DOI: 10.1038/s41541-017-0008-6

Abstract

Despite widespread use of the Bacillus Calmette-Guerin vaccine, tuberculosis, caused by infection with

Conflict of interest statement

COMPETING INTERESTS Aeras TB Vaccine Foundation, a non-profit organization, has licensed technology from OHSU of which Drs. David and Deborah Lewinsohn are inventors and which is used in this research

References

  1. J Virol. 2004 Mar;78(5):2187-200 - PubMed
  2. Infect Immun. 1991 Jun;59(6):1905-10 - PubMed
  3. PLoS Pathog. 2007 Sep 21;3(9):1240-9 - PubMed
  4. Future Microbiol. 2012 Apr;7(4):513-8 - PubMed
  5. Clin Chest Med. 2009 Dec;30(4):811-26, x - PubMed
  6. Am J Respir Crit Care Med. 2003 Dec 1;168(11):1346-52 - PubMed
  7. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7534-9 - PubMed
  8. J Exp Med. 2003 Sep 1;198(5):693-704 - PubMed
  9. Immunology. 1994 Nov;83(3):341-6 - PubMed
  10. Nat Rev Microbiol. 2010 Sep;8(9):668-74 - PubMed
  11. Nature. 2000 Apr 20;404(6780):884-8 - PubMed
  12. Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53 - PubMed
  13. Annu Rev Immunol. 1999;17:51-88 - PubMed
  14. Front Immunol. 2012 Mar 05;3:40 - PubMed
  15. Microbes Infect. 2005 May;7(5-6):911-21 - PubMed
  16. Annu Rev Immunol. 2004;22:599-623 - PubMed
  17. J Virol. 2003 May;77(9):5226-40 - PubMed
  18. J Exp Med. 2002 Dec 2;196(11):1473-81 - PubMed
  19. Proc Natl Acad Sci U S A. 2011 May 31;108(22):9178-83 - PubMed
  20. Adv Exp Med Biol. 2013;783:141-63 - PubMed
  21. J Med Virol. 1994 May;43(1):103-10 - PubMed
  22. Am J Respir Crit Care Med. 2012 Jan 15;185(2):206-12 - PubMed
  23. PLoS One. 2013 Dec 04;8(12):e81564 - PubMed
  24. PLoS One. 2008 Jan 30;3(1):e1502 - PubMed
  25. Clin Infect Dis. 1992 Sep;15(3):540-7 - PubMed
  26. Microbes Infect. 2005 May;7(5-6):922-31 - PubMed
  27. Immunol Rev. 2011 Mar;240(1):25-39 - PubMed
  28. J Immunol. 2011 Jan 15;186(2):1068-80 - PubMed
  29. Immunome Res. 2007 Dec 14;3:10 - PubMed
  30. J Immunol Methods. 2004 May;288(1-2):19-34 - PubMed
  31. Lancet. 2013 Mar 23;381(9871):1021-8 - PubMed
  32. Immunol Cell Biol. 2009 May-Jun;87(4):279-86 - PubMed
  33. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4204-8 - PubMed
  34. PLoS Pathog. 2012;8(5):e1002607 - PubMed
  35. Infect Immun. 1992 Nov;60(11):4781-92 - PubMed
  36. PLoS Pathog. 2013 Jan;9(1):e1003130 - PubMed
  37. Mucosal Immunol. 2013 Jan;6(1):35-44 - PubMed
  38. PLoS One. 2013 Jun 21;8(6):e67016 - PubMed
  39. Front Microbiol. 2014 Oct 08;5:517 - PubMed
  40. Vaccine. 2014 Feb 3;32(6):712-6 - PubMed
  41. Immunobiology. 1994 Oct;191(4-5):537-47 - PubMed
  42. Science. 1998 Oct 2;282(5386):121-5 - PubMed
  43. Cold Spring Harb Perspect Med. 2014 May 22;4(7):a018465 - PubMed
  44. Clin Dev Immunol. 2011;2011:497203 - PubMed
  45. Annu Rev Immunol. 2009;27:393-422 - PubMed

Publication Types

Grant support